People: Immuron Ltd (IMC.AX)

IMC.AX on Australia Stock Exchange

0.01AUD
1 Sep 2014
Price Change (% chg)

$0.00 (+16.67%)
Prev Close
$0.01
Open
$0.01
Day's High
$0.01
Day's Low
$0.01
Volume
1,227,999
Avg. Vol
--
52-wk High
--
52-wk Low
--

Search Stocks

Summary

Name Age Since Current Position

Roger Aston

2012 Non-Executive Chairman of the Board

Amos Meltzer

2013 Interim Chief Executive Officer

Phillip Hains

2013 Joint Company Secretary

Peter Vaughan

2013 Joint Company Secretary

Stephen Anastasiou

2013 Non-Executive Director

Daniel Pollock

2012 Independent Non-Executive Director

Biographies

Name Description

Roger Aston

Dr. Roger Aston, Ph.D., is Non-Executive Chairman of the Board of Immuron Limited since October 8, 2012. He was appointed Non-Executive Director on May 5, 2012. Within the Company he is Member of Audit and Risks Committee. Dr. Aston has more than 20 years of experience in the pharmaceutical and biotech industries. Dr. Aston was previously the Chief Executive Officer and a Director of Mayne Pharma Group Limited. Prior to his position at Mayne Pharma, some of his previous positions have included CEO of Peptech Limited (Australia), Director of Cambridge Antibody Technology Limited (UK) and Chairman of Cambridge Drug Discovery Limited (UK – now Bio Focus plc). Dr. Aston was also founder and CEO of Biokine Technology Ltd (UK) prior to its acquisition by the Peptech Group. Dr. Aston was also a director of pSivida Ltd. During the past 20 years of his career, Dr. Aston has been closely involved in the development of a number of pharmaceutical and biotechnology companies. Dr. Aston has experience including negotiating global license agreements, overseeing product registration activities with the FDA, the establishment and implementation of guidelines and operating procedures for manufacturing and clinical trials, overseeing manufacturing of human and veterinary products, private and public fund raising activities and the introduction of corporate governance procedures. Other current directorships include IDT Limited.

Amos Meltzer

Mr. Amos Meltzer has been Interim Chief Executive Officer of Immuron Ltd since March 2013. He has played a role in the commercial expansion of a number of biotechnology companies, and brings with him a pharmaceutical partnering and licensing experience required to meet the Company's business objectives.

Phillip Hains

Mr. Phillip Hains is Joint Company Secretary of Immuron Ltd since April 19, 2013. Mr. Hains is a Chartered Accountant and specialist in the public company environment. He services the needs of a number of public company boards and related committees as both their Company Secretary and Chief Financial Officer. He has had over 20 years’ experience in providing accounting, administration, compliance and general management services to both ASX and NASDAQ listed companies.

Peter Vaughan

Mr. Peter Vaughan is Joint Company Secretary of Immuron Ltd since April 19, 2013. Mr. Vaughan is also a Chartered Accountant who has worked in the listed company environment for 10 years across a number of industries serving various finance roles, including the roles of Company Secretary and Chief Financial Officer.

Stephen Anastasiou

Mr. Stephen Anastasiou is Non-Executive Director of Immuron Ltd effective May 28, 2013. He holds a Bachelor of Science (Hons), Graduate Diploma in Marketing and a Masters of Business Administration. He has over 20 years’ experience in general management, marketing and strategic planning within the healthcare industry. He is management consultant with KPMG Peat Marwick and Director and shareholder of a number of unlisted private companies. Mr. Anastasiou has previously led project teams in a diverse range of market development and strategic planning projects in both the public and private sector. He is also a director and shareholder of a number of unlisted private companies, covering a variety of industry sectors that include healthcare and funds management. Mr Anastasiou’s companies have participated in several corporate transactions involving business units and brands of multinational and Australian companies.

Daniel Pollock

Mr. Daniel Pollock is Director of Immuron Ltd since October 11, 2012. Daniel Pollock is a lawyer admitted in both Scotland and Australia and holding Practicing Certificates in both Jurisdictions. He is sole practitioner in his own legal firm based in Melbourne, Australia which operates internationally and specializes in commercial law. Daniel is Chairman and Company Secretary of Amaero Pty Ltd, a company established to commercialise laser based additive manufacturing emerging from Monash University. He is also Executive Director and co-owner of Great Accommodation P/L a property management business operating in Victoria. Daniel has had historical involvement as a seed investor and Board member of a number of small unlisted companies. The most recent of these was an E-Pharmacy company where he was heavily involved in its commercial growth and ultimate sale to a large listed health services company.

Basic Compensation

Name Fiscal Year Total

Roger Aston

--

Amos Meltzer

246,300

Phillip Hains

--

Peter Vaughan

--

Stephen Anastasiou

--

Daniel Pollock

--
As Of 29 Jun 2012

Options Compensation

Search Stocks